Dimitrios Chondros

Dimitrios Chondros, MD, currently serves as SVP and Therapeutic Area Head of Oncology at Ipsen since 2021. Prior experience includes roles as SVP and Head of Global Clinical Development at Ultragenyx Pharmaceutical Inc. (2020-2021) and Chief Medical Officer at Halozyme Therapeutics, Inc. (2015-2020). Additional positions span from Assoc. Group Medical Director at Genentech (2009-2015), including an international assignment at Roche, to Medical Director at Cell Genesys Inc. (2005-2008) and Clinical Project Scientist at Grünenthal (1999-2005). Earlier career stages involved residency and fellowship in general surgery at Hochtaunuskliniken Bad Homburg, culminating in board certification as a General Surgeon. Educational credentials feature an MD in Surgery from the University of Zurich, a postgraduate course in Clinical Pharmacology from Tufts University School of Medicine, and executive education from Harvard Business School and IMD.